WVXU: Certain cancer treatments & COVID-19 could lead to death
Recent research shows combinations of treatments given at certain times could mean worse outcomes
A University of Cincinnati study found that cancer patients undergoing a combination of chemotherapy and immunotherapy one to three months prior to a COVID-19 diagnosis have a greater risk of death than patients who haven't undergone cancer treatment in the past year.
These findings were presented Saturday at the European Society for Medical Oncology Virtual Congress 2020.
Lead author Trisha Wise-Draper, MD, PhD, associate professor of medicine in the Division of Hematology and Oncology at UC, UC Health oncologist and member of the UC Cancer Center, and her team analyzed 3,600 patients from 122 institutions across the country for this study.
"Any way you slice it, this is not good news for patients who are fighting cancer," she says. "Targeted therapies, especially those causing immune cell depletion, used one to three months before (the diagnosis of COVID-19) are associated with very high mortality, up to 50%."
Photo of chemotherapy courtesy of the National Cancer Institute.
Next Lives Here
The University of Cincinnati is classified as a Research 1 institution by the Carnegie Commission and is ranked in the National Science Foundation's Top-35 public research universities. UC's graduate students and faculty investigate problems and innovate solutions with real-world impact. Next Lives Here.
Related Stories
WLWT: Tips to fight off bad allergy symptoms
April 18, 2024
The University of Cincinnati's Ahmad Sedaghat spoke with WLWT about how Cincinnati's geography tends to make allergy symptoms worse and tips to fight off those symptoms.
Medscape: Skin adverse events rare after immunotherapy to treat...
April 17, 2024
Medscape highlighted University of Cincinnati research published in JAMA Dermatology that found skin adverse events were rare following immunotherapy treatments for certain skin cancers.
UC researchers develop new CPAP device
April 17, 2024
Researchers at the University of Cincinnati are developing a VortexPAP machine that takes advantage of vortex airflow technology. A preliminary clinical study with current CPAP users demonstrated that the VortexPAP can deliver the pressure levels that are used in the subjects’ CPAP therapy, but the mask is more comfortable to wear. It has a minimalistic design that is less intrusive and barely touches the patient’s face.